跳至主要内容
临床试验/NCT01171781
NCT01171781Unknown2 期

A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma

Samsung Medical Center1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
110
试验地点
1
主要终点
progression free survival rate at 3 years

研究概览

简要总结

The study try to show the weekly cisplatin based CCRT is not inferior to 3-weekly cisplabe based CCRT in terms of 3-yr progression free survival rate in advanced nasopharyngeal carcinoma

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • histologically confirmed nasopharyngeal carcinoma age of 18 years or over stage II ~ IVb no history of chemotherapy, radiotherapy, or immunotherapy for NPC with measurable lesion based on RECIST 1.1 ECOG PS 0 ~2 good organ function (liver, renal, hematologic)

排除标准

  • active infectious disease requiring antibiotics uncontrolled heart disease pregnancy and on feeding state history of other malignancy within 5 years before enrollment, except for well treated non-melanomatous skin cancer, in situ cervical cancer, thyroid cancer

研究组 & 干预措施

3 weekly CDDP based CCRT

Active Comparator

radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin

干预措施: cisplatin (3 weekly) (Drug)

weekly cisplatin based CCRT

Experimental

radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy

干预措施: cisplatin (weekly) (Drug)

结局指标

主要结局

progression free survival rate at 3 years

时间窗: 36 months

次要结局

  • overall survival rate(36 months)
  • objective response rate(36 months)
  • toxicity(36 months)
  • quality of life(36 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Unknown
3 期
Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal CarcinomaNasopharyngeal Carcinoma
NCT02301208He Xia120
已完成
3 期
Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical CancerCervical Cancers
NCT01097252Korea Cancer Center Hospital104
进行中(未招募)
2 期
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPCHead and Neck Cancer
NCT00997906National Cancer Centre, Singapore172
撤回
2 期
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive WomenCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedFIGO Stage IIB Cervix CarcinomaFIGO Stage III Cervix CarcinomaFIGO Stage IVA Cervix CarcinomaHIV Infection
NCT03834571AIDS Malignancy Consortium
已完成
2 期
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid Leukemia
NCT00634244National Cancer Institute (NCI)92